Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Receivables (2016 - 2025)

Lineage Cell Therapeutics' Change in Receivables history spans 16 years, with the latest figure at $827000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 254.94% year-over-year to $827000.0; the TTM value through Dec 2025 reached $316000.0, up 398.11%, while the annual FY2025 figure was $316000.0, 398.11% up from the prior year.
  • Change in Receivables reached $827000.0 in Q4 2025 per LCTX's latest filing, up from -$130000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $827000.0 in Q4 2025 to a low of -$50.3 million in Q1 2022.
  • Average Change in Receivables over 5 years is -$2.4 million, with a median of $89000.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 37374.81% in 2022, then soared 2916.67% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $753000.0 in 2021, then tumbled by 114.34% to -$108000.0 in 2022, then soared by 382.41% to $305000.0 in 2023, then decreased by 23.61% to $233000.0 in 2024, then surged by 254.94% to $827000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Change in Receivables are $827000.0 (Q4 2025), -$130000.0 (Q3 2025), and $43000.0 (Q2 2025).